A prospective, randomized, controlled, interventional, single-blinded, multi-center, post-market, global cardiac resynchronization therapy (CRT) in heart failure (HF) clinical study.
Post-approval study is to provide safety and effectiveness data regarding the use of the CardioMEMS HF System in a commercial setting.
Carotid revascularization and medical management for asymptomatic carotid stenosis trial.
DalCor Pharma UK
A 12-week randomized, double-blind, placebo-controlled trial to evaluate the effects of once-daily dapagliflozin 10 mg on heart failure disease-specific biomarkers (BNP and NTproBNP), symptoms, health status, and quality of life in patients with type 2 diabetes and chronic heart failure with reduced systolic function.
Getting to an improved understanding of low-density lipoprotein cholesterol and dyslipidemia management (GOULD): a registry of high cardiovascular risk subjects in the United States.
Integrated diagnostics driven diuretic and chronic medication management for heart failure (INTERVENE-HF), a prospective, nonrandomized, multicenter, feasibility study.
An international, multicenter, randomized, double-blind, placebo controlled phase 3 trial investigating the efficacy and safety of rivaroxaban to reduce the risk of major thrombotic vascular events in patients with symptomatic peripheral artery disease undergoing lower extremity revascularization procedures.
A multicenter, randomized, double-blind, double dummy, parallel group, active-controlled 8-week study to evaluate the effect of sacubitril and valsartan (LCZ696) versus enalapril on changes in NT-proBNP and safety and tolerability of in-hospital initiation of LCZ696 compared to enalapril in HFrEF patients who have been stabilized following hospitalization for acute decompensated heart failure (ADHF).
A single-arm study of the Revolution™ Peripheral Atherectomy System in subjects with peripheral arterial disease (PAD).